Analysis of the cag pathogenicity island and IS605 of Helicobacter pylori strains isolated from patients with gastric cancer in Japan

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 1, 2004, Pages 13-16

  Deguchi, R ^a   Igarashi, M ^b   Watanabe, K ^b   Takagi, A ^b  

^a TOKAI UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAGA PROTEIN;

ANTIBODY BLOOD LEVEL; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE INSERTION SEQUENCE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; NONHUMAN; PATHOGENICITY ISLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; STOMACH CANCER;

EID: 4344630444     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01982.x     Document Type: Conference Paper

References (14)

1. International Agency for Research on Cancer: Schistosomes, liver flukes and Helicobacter pylori. IARC Monograph: Evaluation of Carcinogenic Risks in Humans. IARC 1994; 61: 188.
2. Deguchi R, Takagi A, Kawata H, Inoko H, Miwa T. Association between CagA+ Helicobacter pylori infection and p53, BAX and transforming growth factor-B-R-II gene mutations in gastric cancer patients. Int J Cancer 2001; 91: 481-5.
3. Maeda S, Yoshida H, Ikenoue T, et al. Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut 1999; 44: 336-41.
4. Owen RJ, Peters TM, Varea R, Teare EL, Saverymuttu S. Molecular epidemiology of Helicobacter pylori in England. Prevalence of Cag pathogenicity island markers and is605 presence in relation to patient age and severity of gastric disease. Immunol Med Microbiol 2001; 30: 65-71.
5. Slater E, Owen RJ, Williams M, Pounder RE. Conservation of the cag pathogenicity island of Helicobacter pylori: associations with vacuolating cytotoxin allele and IS605 diversity. Gastroenterology 1999; 117: 1308-15.
6. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297-301.
7. Palli D, Menegatti M, Masala G, et al. Helicobacter pylori infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy. Aliment Pharmacol Ther 2002; 16: 1015-20.
8. Sande N, Nikulin M, Nilsoon I, et al. Increased risk of developing atrophic gastritis in patients infected with CagA+ Helicobacter pylori. Scand J Gastroenterol 2001; 36: 928-33.
9. Yang G, Hu F, Jia J. Relation between infection of CagA-positive Helicobacter pylori and upper gastrointestinal diseases. Zhonghua Yi Xue Za Zhi 2001; 81: 648-50.
10. Maeda S, Kanai F, Ogura K, et al. High seropositivity of anti-CagA antibody in Helicobacter pylori-infected patients irrelevant to peptic ulcers and normal mucosa in Japan. Dig Dis Sci 1997; 42: 1841-7.
11. Audibert C, Burucoa C, Janvier B, Fauchere JL. Implication of the structure of the Helicobacter pylori cag pathogenicity island in induction of interleukin-8 secretion. Infect Immun 2001; 69: 1625-9.
12. Crabtree JE, Kersulyte D, Li SD, Lindley IJ, Berg DE. Modulation of Helicobacter pylori induced interleukin-8 synthesis in gastric epithelial cells mediated by cag PAI encoded VirD4 homologue. J Clin Pathol 1999; 52: 653-7.
13. Asahi M, Azuma T, Ito T, et al. Helicobacter pylori CagA can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med 2000; 191: 593-602.
14. Segal ED, Cha J, Lo J, Falkow S, Tompkins LS. Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci 1999; 96: 14559-64.